TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private ...

Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systemsTORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ...

Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function ...

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

– Aligns well with CMS 2025 Final Rule establishing Urology APC Level 7 reimbursement for TULSA procedure at all 3 sites of service – Magnetom Free.Max from Siemens Healthineers is an innovative MR ...

Profound Medical ( ($TSE:PRN) ) has shared an announcement. Profound Medical announced that The Johns Hopkins Hospital has performed its first ...

CEO Arun Swarup Menawat summarized that "our sales team has been stabilized. That, combined with our large and growing TULSA-PRO pipeline, continues to drive our confidence in our ability to deliver ...

TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Profound Medical (PROF) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...